DUBLIN — Perrigo on Wednesday announced that the Food and Drug Administration had approved the company’s generic KlorCon (potassium chloride) extended-release tablets.
The drug, which is indicated to treat and prevent hypokalemia, or low potassium levels, will be available in 600- and 750-mg dosage strengths. Sales of the drug for the 12 months ending Sept. 15 were $81 million.